Varying approaches: granting SPCs in Europe

Supplementary protection certificates (SPCs) are a hugely important intellectual property right for the pharmaceutical industry as they can extend patent protection for a particular pharmaceutical product for up to five additional years.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.

Big Pharma

Part II: The race to replace semaglutide heats up

23 March 2026 With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?

Big Pharma

Sandoz strikes fresh biosimilar deal with South Korean biotech

19 March 2026 The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.

More features

Appeals court eases Teva’s headache with reversal

Baker McKenzie strengthens IP bench with new German lead

Cancer drug researcher hit with suit over mutation-targeting tools

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Court narrows Mylan’s Copaxone suit but key claims survive

IP finance gap risks startup exodus, EUIPO warns

Patent office fee increases: What applicants must know

LSPN Awards USA: Meet the judges

Varying approaches: granting SPCs in Europe

More on this story

Editor's picks

Editor's picks

More features